Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c
Get Alerts SLXN Hot Sheet
Join SI Premium – FREE
Silexion Therapeutics (NASDAQ: SLXN) reported Q2 EPS of ($5.17), $7.93 better than the analyst estimate of ($13.10).
For earnings history and earnings-related data on Silexion Therapeutics (SLXN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Levi (LEVI) Tops Q3 EPS by 12c; raises guidance
- IBM selected for third phase of DARPA quantum benchmarking program
- Cruz Battery Metals to consolidate shares and rebrand as Cruz Mining
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!





Tweet
Share